Outcomes in COVID-19 gimsilumab studies

All studies   Mortality   Serious outcomes   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies -10% 1 225 Improvement, Studies, Patients Relative Risk Mortality -10% 1 225 RCTs -10% 1 225 Late -10% 1 225 Gimsilumab for COVID-19 c19early.org November 2025 Favorsgimsilumab Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ BREATHE Criner (DB RCT) -10% 1.10 [0.70-1.80] death 32/113 31/112 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.67 Late treatment -10% 1.10 [0.70-1.80] 32/113 31/112 10% higher risk All studies -10% 1.10 [0.70-1.80] 32/113 31/112 10% higher risk 1 gimsilumab COVID-19 study c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.67 Effect extraction pre-specified(most serious outcome) Favors gimsilumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ BREATHE Criner (DB RCT) -10% 1.10 [0.70-1.80] 32/113 31/112 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.67 Late treatment -10% 1.10 [0.70-1.80] 32/113 31/112 10% higher risk All studies -10% 1.10 [0.70-1.80] 32/113 31/112 10% higher risk 1 gimsilumab COVID-19 mortality result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.67 Favors gimsilumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ BREATHE Criner (DB RCT) -10% 1.10 [0.70-1.80] death 32/113 31/112 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.67 Late treatment -10% 1.10 [0.70-1.80] 32/113 31/112 10% higher risk All studies -10% 1.10 [0.70-1.80] 32/113 31/112 10% higher risk 1 gimsilumab COVID-19 serious outcome c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.67 Effect extraction pre-specified(most serious outcome) Favors gimsilumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ BREATHE Criner (DB RCT) -10% 1.10 [0.70-1.80] death 32/113 31/112 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.67 Late treatment -10% 1.10 [0.70-1.80] 32/113 31/112 10% higher risk All studies -10% 1.10 [0.70-1.80] 32/113 31/112 10% higher risk 1 gimsilumab COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.67 Effect extraction pre-specified(most serious outcome) Favors gimsilumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ BREATHE Criner (DB RCT) -10% 1.10 [0.70-1.80] 32/113 31/112 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.67 Late treatment -10% 1.10 [0.70-1.80] 32/113 31/112 10% higher risk All studies -10% 1.10 [0.70-1.80] 32/113 31/112 10% higher risk 1 gimsilumab COVID-19 RCT mortality result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.67 Favors gimsilumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ BREATHE Criner (DB RCT) -10% 1.10 [0.70-1.80] death 32/113 31/112 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.67 Late treatment -10% 1.10 [0.70-1.80] 32/113 31/112 10% higher risk All studies -10% 1.10 [0.70-1.80] 32/113 31/112 10% higher risk 1 gimsilumab COVID-19 peer reviewed studies c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.67 Effect extraction pre-specified(most serious outcome) Favors gimsilumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ BREATHE Criner (DB RCT) -10% 1.10 [0.70-1.80] death 32/113 31/112 Improvement, RR [CI] Treatment Control BREATHE Criner (DB RCT) -22% 1.22 [0.78-1.91] death 32/113 26/112 Gimsilumab COVID-19 outcomes c19early.org November 2025 Favors gimsilumab Favors control